共发表各类科研论文90余篇，所列为2010年以来以第一或通讯作者（*）发表的论文

89.Wei Liu,Shuzhi Lin,Xiaoying Zhu,Lin Yin,Qian Liu,Shuang Lei,Bianling Feng*. Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database.[J].Frontiers in Immunology,2024,15:1433075.(IF:5.7,最有学术影响力的国际期刊）

88.Shuzhi Lin,Shuang Lei,Wei Liu,Xiaoying Zhu,Lin Yin,Qian Liu,Bianling Feng*. Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study.[J].International Journal of Clinical Pharmacy,2024,46:1076-1090.(IF:2.6）

87.刘茜,任碧琪,牛江,林书智,雷霜,刘炜,朱小莹,尹林,冯变玲*.陕西省医疗机构药事服务费设立情况的调查与分析[J].医药导报,2024,43(09):1416-1422.

86.Xiaoying Zhu,Biqi Ren,Wei Liu,Shuang Lei,Shuzhi Lin,Qian Liu,Lin Yin,Bianling Feng*. The short- and long-term effects of community-family-doctor-based type 2 diabetes self-management interventions.[J].Public Health,2024,230:96-104.(IF:5.2,国际知名学术刊物）

85.朱小莹,任碧琪,苏欣月,雷霜,林书智,刘炜,冯变玲*.西安市药店慢病管理的2型糖尿病患者用药和血糖控制情况分析[J].药物流行病学杂志,2024,33(02):184-193.

84.Shuzhi Lin,Shuang Lei,Wei Liu,Xiaoying Zhu,Biqi Ren,Bianling Feng*. Safety analysis of therapeutic drugs for breast cancer patients and construction of a predictive model for serious adverse drug reactions.[J].European journal of clinical pharmacology,2024,80(2):249-259.(IF:2.9,国际知名学术刊物）

83.Shuang Lei, Ningsheng Wang,Biqi Ren,Shuzhi Lin,Bianling Feng*. Safety analysis of antineoplastic drugs for lung cancer: a retrospective analysis based on Shaanxi Province in Western China.[J].Expert Opinion on Drug Safety,2024,23(1):99-105.(IF:4.011）

82.雷霜,冯变玲*,任碧琦,林书智,刘炜,朱小莹,戴盛宇,迟易泓,黄瀚博,谢华,刘晓阳.基于人工智能的药品投诉类案例信息识别及分类效能评估[J].医药导报,2023,42(10):1589-1593.

81.王宁生,赵楠,任碧琦,陈月,向玉芳,尤海生,赵华,冯变玲*.基于陕西省抗肿瘤药物不良反应报告的抗肿瘤用药安全性分析[J].中国药学杂志,2022,57(24):1818.

80.Shuzhi Lin,Ningsheng Wang,Biqi Ren,Shuang Lei,Bianling Feng*.Use of Failure Mode and Effects Analysis (FMEA) for Risk Analysis of Drug Use in Patients with Lung Cancer.[J].International Journal of Environmental Research and Public Health,2022,19(23):15428.(IF:4.614,最有学术影响力的国际期刊)

79.Biqi Ren,Ningsheng Wang,Shuang Lei, Shuzhi Lin,Yue Chen, Lianye Liu,Yufang Xiang,Bianling Feng*.Effects of community family doctors-led intervention for self-management and medication adherence in type 2 diabetes mellitus patients: study protocol of a cluster randomised controlled trial[J].BMJ Open,2022,12(7):e058670(IF:3.006,国际知名学术刊物)

78.向玉芳,孙辉,陈月,王宁生,罗世书,张智,冯变玲*.2型糖尿病降糖药不良反应及联合用药情况分析[J].中国药物警戒,2022,19(3):313.

77.Ningsheng Wang,Yue Chen,Biqi Ren,Yufang Xiang,Nan Zhao,Xianyan Zhan,Bianling Feng*.A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China[J].BMC Health Services Research,2022,22(1):318.(IF:2.908,最有学术影响力的国际期刊)

76.Ningsheng Wang,Biqi Ren,Haisheng You,Yue Chen,Shuzhi Lin,Shuang Lei,Bianling Feng*.Assessment of medication adherence,medication safety awareness and medication practice among patients with lung cancer:A multicentre cross-sectional study[J].Health Expectations,2022,25(2):791.(IF:3.318,最有学术影响力的国际期刊)

75.王振,冯艾,冯变玲*.药品产业链供需协作共享服务模式研究[J].中国医药工业杂志,2019,50(1):125.

74.刘生元,闫抗抗,叶丹,张雨晨,陈月,王宁生,袁怀霞,冯变玲*.低价药政策对低价药品价格的影响评估[J].医药导报,2021,40(2):

287.

73.Yufang Xiang,Biqi Ren,Yue Chen,Minghuan Jiang,Ningsheng Wang,Rui Niu,Bianling Feng*.Predictors of glycemic control among patients with type 2 diabetes in Western China:Amulti-center cross sectional study[J].Biological and Pharmaceutical Bulletin,2021:620.(IF:2.233)

72.Yue Chen,Yuejin Wang,Ningsheng Wang,Yufang Xiang,Rui Zhang,Jizhen Xiao,Hanjun Liu,Bianling Feng*.Knowledge,attitude,and practice regarding pharmacovigilance among the general public in Western China: a cross-sectional study[J].Current Medical Research and Opinion,2021,37(1):101.(IF:2.580,最有学术影响力的国际期刊)

71.Rui Niu,Yue Chen,Yufang Xiang,Ying Liu,Jiadong Guo,Bianling Feng*.Comparison of Three Different Data Sources of Adverse Drug Reactions Using Adverse Drug Reaction Data of Fluorouracil for Gastric Cancer as an Example[J].Biological and Pharmaceutical Bulletin,2020,43(10):1476.(IF:2.233)

70.陈月,牛瑞,向玉芳,赵楠,白军峰,冯变玲*.江苏省和陕西省药品不良反应报告质量对比分析[J].西北药学杂志,2020,35(05):762.

69.向玉芳,牛瑞,苟喜兰,崔珍逖,司佩茹,葛帅,杨舒勋,冯变玲*.陕西省糖尿病患者血糖监测及用药情况[J].医药导报,2019,38(11):1514.

68.Yue Chen,Rui Niu,Yufang Xiang,Ningsheng Wang,Junfeng Bai,Bianling Feng*.The Quality of Spontaneous Adverse Drug Reaction Reports in China:A Descriptive Study[J].Biological and Pharmaceutical Bulletin,2019,42(12).（IF:2.233）

67.牛瑞,向玉芳,张智,赵楠,苟喜兰,冯变玲*.药品不良反应报告质量评估体系的建立[J].医药导报,2019,38(06):815.

66.牛瑞,向玉芳,白军锋,赵楠,樊瑞,姚雪林,冯变玲*.2015—2017年陕西省药品不良反应报告表质量评价[J].医药导报,2019,38(07):

967.

65.Rui Niu,Yufang Xiang,Tingting Wu,Zhi Zhang,Yue Chen,Bianling Feng*.The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China[J].Expert Opinion on Drug Safety,2019,18(1).（IF:3.383）

64.向玉芳,牛瑞,刘影,冯变玲*.从药物不良反应谈老年高血压患者未来的社区管理[J].中国全科医学,2018,21(27):3307.

63.刘影,牛瑞,张雪梅,王小莉,冯变玲*.英夫利西单抗治疗强直性脊柱炎的药物经济学系统评价[J].药物流行病学杂志,2018,27(6):410.

62.刘影,牛瑞,张雪梅,冯变玲*.类风湿关节炎和强直性脊柱炎门诊特殊诊疗项目的执行现状及影响因素[J].医药导报,2018,37(6):771.

61.Xuemei Zhang,Rui Niu,Bianling Feng,Jiadong Guo,Ying Liu,Xinyu Liu.Adverse drug reaction reporting in institutions across six Chinese provinces:across-sectional study[J].Expert Opinion on Drug Safety,2018,18(1).(IF:3.220)

60.牛瑞,刘影,向玉芳,冯变玲*.3种来源的药品不良反应数据比较分析[J].药物流行病学杂志,2018,27(2):98.

59.牛瑞,刘影,向玉芳,冯变玲*.药品价格谈判国际经验与国内实践的比较研究[J].中国卫生政策研究,2017,10(6):25.

58.刘影,付葵,成东莹,张雪梅,郭佳栋,冯变玲*.强直性脊柱炎住院患者用药情况分析与评价[J].中国药事,2017,31(5):524.

57.郭佳栋,张雪梅,刘影,冯变玲*.8种胃癌化疗药物与药品不良反应的聚类关系分析[J].中国药事,2017,31(5):584.

56.郭佳栋,张雪梅,刘影,冯变玲*.基于数据挖掘技术对胃癌化疗药物不良反应关联性研究[J].药物流行病学杂志,2017,26(1):46.

55.张雪梅,郭佳栋,刘影,冯变玲*,杨世民.药品不良反应监测体系评估指标建立的研究[J].中国药事,2017,31(1):107.

54.张雪梅,郭佳栋,冯变玲*,杨世民.药品生产企业药品不良反应工作的调查研究[J].医药导报,2016,35(8):902.

53.冯变玲*,郭增军,王晓美,杨广德,宋杰.药学功能模拟实验室的构建设想[J].药学教育,2016,32(2):68.

52.郭佳栋,冯变玲*,张雪梅,蔡佳慧,赵妍,王丽云.卡培他滨治疗胃癌疗效及安全性的系统评价[J].药物流行病学杂志,2016,25(2):69.

51.张雪梅,郭佳栋,冯变玲*,杨世民.西部地区部分省份药品不良反应报告主体实证研究[J].中国药物警戒,2015,12(12):740.

50.张雪梅,郭佳栋,冯变玲*,杨世民.我国六省份医疗机构药品不良反应工作调查研究[J].中国药物警戒,2015,12(10):603.

49.冯变玲,杨世民,赵晓红,韩颖,彭涛,张智,赵超.陕西省药品不良反应报告主体工作现状的实证研究[J].医药导报,2015,34(10):1401.

48.张雪梅,郭佳栋,冯变玲*,杨世民.陕西省和四川省药品不良反应报告单位调查研究[J].中国药房,2015,26(30):4185.

47.张雪梅,郭佳栋,冯变玲*,杨世民,肖勋霞.河南省和河北省药品不良反应报告单位调查研究[J].中国药房,2015,26(24):3316.

46.张雪梅,冯变玲*,杨世民,肖勋霞.江苏省和广东省药品不良反应报告单位调查研究[J].中国药房,2015,26(21):2884.

45.郭佳栋,张雪梅,白军锋,张智,冯变玲*.陕西省药品不良反应报告主体工作现状的实证研究[J].药物流行病学杂志,2015,24(5):282.

44.郭佳栋,冯变玲*,张雪梅,杨世民,董卫华,吴谦.胃癌患者5-氟尿嘧啶用药安全性Meta分析[J].中国药业,2015,24(2):27.

43.冯变玲*,赵超,杨世民,刘花,彭涛.药品不良反应监测质量评估指标调查分析[J].医药导报,2014,33(3):411.

42.刘花,冯变玲*,杨世民,张智.我国省级药品不良反应监测机构发展现状的调查分析[J].中国药房,2014,25(12):1062.

41.刘花,冯变玲*,杨世民,张智.我国省级ADR监测机构工作人员对ADR监测工作认知情况的调查分析[J].中国药房,2014,25(4):300.

40.冯变玲*,傅强,郭佳栋,张雪梅,陈有亮,杨世民,张永涛.中职药剂专业国家级师资培训效果分析[J].药学教育,2014,30(4):53.

39.刘花,冯变玲*,杨世民.药品不良反应研究现状与展望[J].医药导报,2013,32(10):1384.

38.张兵,冯变玲*,赵晓红,吉天天.青霉素类药物不良反应报告分析[J].西北药学杂志,2013,28(5):524.

37.冯变玲*,赵超,杨世民,张智,吴婷婷,刘花.药品不良反应监测质量评估指标体系的建立[J].药物流行病学杂志,2013,22(10):529.

36.刘花,冯变玲*,杨世民.药品不良反应行为为主体礼仪博弈分析[J].中国药师,2013,16(1):133.

35.Bianling Feng*,Juqing Jin,Changhe Wang,Jie Song,Guangde Yang,Aiguo Zeng. Analysis and retention behavior of isoflavone glycosides and aglycones in Radix Astragali by HPLC with hydroxypropyl-β-cyclodextrin as a mobile phase additive[J].Journal of Separation Science,2012,35,3469.(IF:3.645)

34.冯变玲*,杨世民,贺小红,雷祎.药品不良反应多维关联规则挖掘及预警模型构建[J].中国药事,2012,26(10):1076.

33.冯变玲*,魏芬,杨世民,赵君,雷祎,覃蓝.心脑血管用药不良反应与用药人群间的关联关系分析[J].中国药房,2011,22(36):3389.

32.冯变玲*,杨世民,张抗怀,蓝夏璐,魏芬.心脑血管疾病用药与药物不良反应间的关联关系[J].中国新药与临床杂志,2011,30(1):75.

31.冯变玲*,杨世民,王杰鹏.2004-2009年我国药品不良反应文献源统计分析[J].医药导报,2011,30(4):540.

30.冯变玲*,杨世民,张抗怀,蓝夏璐,魏芬,尤海生.心脑血管疾病用药不良反应与药品品种关系的聚类分析[J].中国药业,2011,20(6):17.

29.冯变玲*,杨世民,叶竹松.普通公众对药品不良反应认知度的调查报告[J].医药导报,2010,29(12):1666.

28.冯变玲*,杨世民,叶竹松.医务人员与公众药品不良反应认知度比较分析[J].中国药学杂志,2010,45(24):1975.